COMIRNATY

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19InfluenzaType 1 DiabetesSARS-Cov2

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

1

COMIRNATY

Pfizer

Approved

172

COVID-19 Vaccine

Moderna

Preclinical

273

Aldactone

Pfizer

Preclinical

14

Nexavar

Bayer

Preclinical

15

Benadryl

PParkedale

Preclinical

16

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—7

Piperacillin/tazobactam

Pfizer

Preclinical

18

Aprotinin

Bayer

Preclinical

19

Antithrombin-III

Octapharma

Preclinical

110

Tpa

UUniversity of Florida

Preclinical

1Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

COVID-1917 trials

Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older

Unknown status·EEverest Medicines (Singapore) Pte. Ltd.·Phase 3·NCT05534048·3,800 enrolled

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05329051·400 enrolled

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05238441·360 enrolled

Show 14 more trials

COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

Terminated·JJules Bordet Institute·Phase 4·NCT05075538·152 enrolled

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Unknown status·WWalvax Biotechnology Co., Ltd.·Phase 1·NCT05396573·120 enrolled

Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 1·NCT04569383·30 enrolled

Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly

Terminated·RRadboud University Medical Center·Phase 2·NCT05977127·48 enrolled

Assessing Immune Response of Different COVID-19 Vaccines in Older Adults

Completed·OOliver Cornely, MD·Phase 2·NCT05160766·323 enrolled

COVID-19 Vaccination of Immunodeficient Persons (COVAXID)

Completed·KKarolinska University Hospital·Phase 4·NCT04780659·539 enrolled

Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT05781191·8,231 enrolled

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Unknown status·WWalvax Biotechnology Co., Ltd.·Phase 1·NCT05394012·120 enrolled

mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

Not yet recruiting·PPharmaJet, Inc.·Phase 2·NCT06919796·40 enrolled

A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

Withdrawn·SSinocelltech Ltd.·Phase 2·NCT05239975

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05239806·400 enrolled

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05238454·600 enrolled

A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

Unknown status·SSinocelltech Ltd.·Phase 3·NCT05323461·1,800 enrolled

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA (CVXGA50) Intranasal COVID-19 Vaccine in Adults

Completed·CCyanVac LLC·Phase 2·NCT06742281·432 enrolled

Vaccination2 trials

Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose

Unknown status·IInstituto de Investigación Hospital Universitario La Paz·Phase 2·NCT05378191·600 enrolled

Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2

Unknown status·MMedical University Innsbruck·Phase 2·NCT04907331·3,000 enrolled

Type 1 Diabetes1 trial

Anti-viral Action Against Type 1 Diabetes Autoimmunity

Recruiting·TTechnical University of Munich·Phase 4·NCT06452654·2,252 enrolled

Influenza1 trial

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

Completed·Pfizer··NCT05858450·3,442,996 enrolled

Efficacy1 trial

IntraDermal Versus Intramuscular Comirnaty® Efficacy Study

Withdrawn·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 3·NCT05029245

4 more indications

Children1 trial

Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years

Completed·Pfizer··NCT06130410·25 enrolled

Immunogenicity1 trial

Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.

Unknown status·SShanghai Zerun Biotechnology Co.,Ltd·Phase 1/2·NCT05490108·60 enrolled

Adult Subject1 trial

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed·BBavarian Nordic·Phase 3·NCT05329220·4,205 enrolled

SARS-CoV21 trial

A Phase 2b, Double-Blind, Multi-Center, Randomized, Comparator-Controlled Trial to Determine the Relative Efficacy, Safety, and Immunogenicity of the Investigational Oral SARS-CoV-2 Vaccine Tablet Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Active, not recruiting·VVaxart·Phase 2·NCT06672055·5,485 enrolled

Details

Drug Info

Related News